Vas Narasimhan Biography - Facts, Childhood, Family Life & Achievements of CEO of Novartis.
Vasant Narasimhan - Wikipedia
Vas Narasimhan of Novartis: 'We Are Not at All Prepared for a Pandemic' - The New York Times
Novartis CEO Vasant Narasimhan on China's coronavirus outbreak
Managing My Energy, Not My Time
Watch CNBC's full interview with Novartis CEO Vas Narasimhan - YouTube
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Vas Narasimhan of Novartis: 'We Are Not at All Prepared for a Pandemic' - The New York Times
novartis: Who is Vas Narasimhan? All about the new global chief executive of Swiss pharma giant Novartis - The Economic Times
Novartis CEO Continues Shake-Up, Says Will Save More Than $1 Billion Annually | Barron's
Novartis' CEO on gene therapy, innovation, and the company pivot - STAT
Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft | Reuters
Vas Narasimhan - PharmTech Focus
CEO Vas Narasimhan tells employees Novartis' deal with Trump lawyer was a mistake he's determined to overcome | Fierce Pharma
Vas Narasimhan: the American trying to reshape Novartis | Financial Times
The CEO of Novartis on Developing Drugs During a Pandemic | WIRED
21 Novartis Ceo Vas Narasimhan Interview Photos and Premium High Res Pictures - Getty Images
The 'student' of leadership who seeks to inspire his employees | Financial Times
Watch CNBC's full interview with Novartis CEO Vas Narasimhan - YouTube
Vas Narasimhan | Fortune
Transforming Standards Of Patient Care And Unbossing The Organisation With Novartis CEO Vas Narasimhan - Outside Lens
Novartis - Speaking at #BSR18, our CEO Vas Narasimhan shares how we are working to help more people get access to the medicines they need #AccessinAction | Facebook
Novartis CEO's 2020 pay drops to $11.6M, no thanks to COVID-19's drag on sales | Fierce Pharma
Interview: Vas Narasimhan, the 'unboss' of Novartis | Business | The Sunday Times
Vas Narasimhan knew what to expect as Novartis CEO—or so he thought: NYT | Fierce Pharma
Vasant Narasimhan | Novartis
